We're pleased to announce Eva Johnsson's appointment as our new Chief Medical Officer (CMO) and VP Clinical Development. With 25 years of executive leadership experience in major pharmaceutical companies as well as the startup world, Eva brings extensive experience in clinical drug development, including regulatory approvals and drug commercialization, and has also held positions in business development and strategy and project management. She has held several senior roles with global clinical responsibility and has had positions in inflammation and pain as well as other therapeutic areas at Grünenthal, AstraZeneca, and BASF Pharma AG/Knoll Läkemedel AB. Eva Johnsson is associate professor at the University of Gothenburg.

This is a significant time for Gesynta Pharma, as we prepare for our clinical Phase II trial of vipoglanstat, in development for the treatment of endometriosis. Eva's expertise will be highly valuable as we move forward with this important clinical program.

Eva is enthusiastic about joining the Gesynta team and contributing to the advancement of our pipeline. Outside of her professional life, she enjoys outdoor activities and has a long-standing involvement with the non-profit sports association Friskis & Svettis. Additionally, Eva has an interest in architecture and design.

We welcome Eva to Gesynta Pharma and look forward to working together, benefiting patients.

Press release: Gesynta Pharma AB Appoints Eva Johnsson as new Chief Medical Officer (CMO) / VP Clinical Development